Home » Small Molecule Inhibitors » ABT-869, ABT869, Linifanib, AL-39324, RG3635
ABT-869, ABT869, Linifanib, AL-39324, RG3635
Catalog Number: SY-ABT-869Availability: In StockSize: | 1 mg, 5 mg, 10 mg, 50 mg, 100 mg |
CAS Number :796967-16-3Alternative Names:ABT-869, ABT869, AL-39324, RG3635 ABT-869, ABT869, Linifanib, AL-39324, RG3635DescriptionMSDS
ABT-869 (Linifanib) is a potent, selective inhibitor of the VEGF and PDGF platelet-derived growth factor families of RTKs. ABT-869 is being studied in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC). Compound is alsocalled Linifanib, AL-39324, RG3635 | |
Tags:ABT-869,ABT869,Linifanib,AL-39324,RG3635;SY-ABT-869/100;SY-ABT-869/50,796967-16-3
Symansis的抑制剂阵列Easy50™阵列是连续稀释的药物阵列,已知它们专门靶向某些细胞信号分子。这些可直接应用于基于酶或细胞的测定,以达到跨越EC 50 和IC 50 的最终浓度 适合该药物的分子靶标。使用生成的信息,研究人员可以快速确定特定的细胞信号通路是否参与正在研究的生物过程。阵列的形式是一个96孔微孔板,包含12列,每列有一种或多种抑制剂,以及8行,每列包含该抑制剂的渐进稀释液,最后一行除外,该行留空作为阴性对照。对于每种抑制剂范围的稀释液从该抑制剂的IC的大约十分之一50 到一成百倍的IC 50